Navigation Links
Synvista Therapeutics Announces First Dosing of SYI-2074 in Clinical Trial for Psoriasis
Date:12/15/2008

MONTVALE, N.J., Dec. 15 /PRNewswire-FirstCall/ -- Synvista Therapeutics, Inc. (NYSE Alternext US: SYI) has dosed the first patient in a 30-patient Phase 2 clinical trial of its proprietary topical GPx-mimetic, SYI-2074, in patients with psoriasis. The trial is planned to be a 28-day multi-center, randomized, double-blind, placebo controlled study to assess the efficacy of topical SYI-2074, applied twice daily, for the treatment of chronic, mild-to-moderate plaque psoriasis in adults. The trial is being conducted in three centers in Israel.

"We are very excited to begin phase 2 clinical trials on SYI-2074 for psoriasis," said Noah Berkowitz, M.D., Ph.D., President and Chief Executive Officer of Synvista Therapeutics. "We believe that there is immense potential to expand the scope of treatment modalities for psoriasis following this trial and look forward to reporting results in the first quarter of 2009."

About SYI-2074

Synvista's GPx mimetic program is based on the rational design of oral and topical drugs that mimic the activity of glutathione peroxidase (GPx), the only enzyme in the human body that reduces oxidized lipids.

GPx is a well validated target for drug development. Animal models have shown that elevated activity of GPx protects animals from experiencing heart attacks and atherosclerosis and reduced levels of GPx put them at risk for those diseases or complications. In humans, research suggests the risk of cardiovascular disease varies inversely with levels of GPx activity (i.e., higher levels of oxidized lipids promote the creation of oxygen free radicals and reactive oxygen species (ROS), such as H2O2, which can promote inflammation).

As noted above, a topical form of our GPx mimetic SYI-2074 is being developed for treatment of mild to moderate plaque psoriasis, an inflammatory disease highly correlated with a molecular signaling
'/>"/>

SOURCE Synvista Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Data Confirm Synvista Therapeutics Haptoglobin Diagnostic Test Kit Success in Rapidly Determining Cardiovascular Risk in Patients with Diabetes
2. Synvista Therapeutics Reports Results of Three Phase 2 Clinical Trials of SYI-2074 in Diabetic Patients with Cardiovascular Disease
3. Synvista Therapeutics Presents New Preclinical Data Demonstrating the Value of Haptoglobin Genotype Testing In Diabetes at ACC Scientific Sessions
4. Synvista Therapeutics Announces Initiation of Phase 2 Study With Alagebrium for Chronic Heart Failure
5. Synvista Announces New Data Showing Haptoglobin Type Predicts Effectiveness of Tight Glycemic Control on Cardiovascular Outcomes in Patients with Diabetes
6. Synvista Collaboration Demonstrates in Preclinical Studies the Mechanism for Defective Cholesterol Transport in Patients with Diabetes
7. Synvista Therapeutics Highlights New Data Demonstrating the Clinical Benefit of Vitamin E Therapy in Patients Identified on the Basis of Haptoglobin Phenotype Testing
8. Synvista Therapeutics Alagebrium Shows Potential for use in Treating Diabetes-Related Gastrointestinal Complications
9. Halozyme Therapeutics Begins Phase 1 Clinical Trial of Bisphosphonate Administered With rHuPH20 Enzyme
10. Halozyme Therapeutics Announces Roche Begins Phase 1 Clinical Trial and Selects Fourth Exclusive Biologic Target
11. Orexigen(R) Therapeutics Announces Changes to Its Clinical Programs and Management Team
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... 31, 2015  Xcelience, a contract development and ... made a structured cash investment in Powdersize, a ... milling, micronization and powder size classification within the ... business while simultaneously adding a complete set of ... capabilities. "As we continue to ...
(Date:7/31/2015)... 2015  Xencor, Inc. (NASDAQ: XNCR ), a ... treatment of autoimmune diseases, asthma and allergic diseases, and ... Hata to its board of directors. ... development is a tremendous asset to our board," said ... officer of Xencor. "Xencor faces a range of opportunities ...
(Date:7/30/2015)... , July 30, 2015  ResMed (NYSE: ... signed a definitive agreement to acquire Curative ... ventilation and sleep-disordered breathing medical devices and ... market reputation in China, combined with ResMed,s global leadership in sleep and ... China suffering from ...
Breaking Medicine Technology:Xcelience Makes Structured Cash Investment in Powdersize 2Xcelience Makes Structured Cash Investment in Powdersize 3Xencor Appoints Yujiro S. Hata to Board of Directors 2Xencor Appoints Yujiro S. Hata to Board of Directors 3ResMed Invests in High-Growth Chinese Sleep and Respiratory Care Market with Curative Medical 2ResMed Invests in High-Growth Chinese Sleep and Respiratory Care Market with Curative Medical 3
... Calif., Oct. 27 ... beamforming technology, analog-front-end semiconductors and solutions for the ... Ultrasound Beamforming Development Kit.  Based on Samplify,s AutoFocus™ ... solution for the ultrasound front end, from probe ...
... Oct. 27 Solos Endoscopy, Inc. (Pink Sheets: ... revenues during the three months ended September 30, 2010 in ... ended September 30, 2009.  This was an increase of 34.8% for ... Despite a down global economy, Solos has been able ...
Cached Medicine Technology:Samplify's New Medical Ultrasound Development Kit Accelerates Equipment Time to Market By Up to 12 Months 2Samplify's New Medical Ultrasound Development Kit Accelerates Equipment Time to Market By Up to 12 Months 3Solos Endoscopy, Inc. Revenue Grows 34.8% for Third Quarter 2010 2
(Date:7/31/2015)... ... July 31, 2015 , ... everMaya ( http://evermaya.com/ ... designer handbag line will be named for Madeline Stuart, an 18-year-old model from ... globally recognized model with Down syndrome, gracing the front pages of publications across ...
(Date:7/31/2015)... ... July 31, 2015 , ... Eldermark Software, the innovative leader ... Aging Services Technologies (CAST) Medication Management Technologies whitepaper. The whitepaper is a compilation ... the benefits of using medication management technologies . , Eldermark’s ...
(Date:7/31/2015)... York (PRWEB) , ... July 31, 2015 , ... Physical therapy for ... limits the patient's quality of life. It keeps the patient from doing what they want ... and may have a hard time using the stairs. The patient's exercise regime may be ...
(Date:7/31/2015)... ... July 31, 2015 , ... The Radiology Business ... Burgess, MD, (R-Tex) presenting “What’s Next for Health Care: A View From Capitol Hill” ... founder of the Congressional Health Caucus, Rep. Burgess has a special understanding of the ...
(Date:7/31/2015)... ... July 31, 2015 , ... In the most recent testosterone lawsuit ... the Northern District of Illinois, Androgel testosterone attorneys report that a “Mini Status Conference” ... was made recording the minutes of the status conference, which was held that day, ...
Breaking Medicine News(10 mins):Health News:everMaya to Launch Madeline Stuart Handbag Line 2Health News:everMaya to Launch Madeline Stuart Handbag Line 3Health News:LeadingAge Selects Eldermark Case Study to Highlight Medication Error Reduction Results 2Health News:LeadingAge Selects Eldermark Case Study to Highlight Medication Error Reduction Results 3Health News:NYDNRehab Is the First Clinic in NYC to Provide APOS Therapy Based on Results of Complete Gait Analysis 2Health News:NYDNRehab Is the First Clinic in NYC to Provide APOS Therapy Based on Results of Complete Gait Analysis 3Health News:Congressional Health Caucus Founder Rep. Michael Burgess, MD, to Speak at RBMA Fall Educational Conference 2Health News:Congressional Health Caucus Founder Rep. Michael Burgess, MD, to Speak at RBMA Fall Educational Conference 3Health News:Testosterone Lawsuit News: Androgel Lawsuit Conference Held 2Health News:Testosterone Lawsuit News: Androgel Lawsuit Conference Held 3Health News:Testosterone Lawsuit News: Androgel Lawsuit Conference Held 4
... the University of Exeter and the Peninsula Medical School ... exposure to perfluorooctanoic acid (PFOA). PFOA is a persistent ... nonstick cookware and stain- and water-resistant coatings for carpets ... Environmental Health Perspectives , The study revealed that people ...
... , Housewife Hits South Florida! ... Lisa Wu Hartwell , one of the stars of ... coming to Boca Raton, Florida .   She isn,t coming ... millions of viewers. , (Photo: http://www.newscom.com/cgi-bin/prnh/20100120/DC41252 ) , (Logo: ...
... ... advanced treatment options with an eye toward aesthetics, limiting visible scarring and focusing on the ... ... a new office in Staten Island, offering comprehensive foot care with a focus on cosmetic ...
... KING OF PRUSSIA, Pa. , Jan. 20 Universal Health ... of Directors voted to pay a cash dividend of $0.05 ... as of March 1, 2010 . , Universal Health Services, Inc. ... acute care and behavioral health hospitals, and ambulatory centers nationwide and in ...
... study has found promising evidence that the older brain,s ... give aging adults a memory advantage over their younger ... shown that aging is associated with a decreased ability ... world-renowned Rotman Research Institute have demonstrated that when older ...
... The American Brain Tumor Association has announced that Alexander ... School of Rosalind Franklin University in North Chicago, is ... Ksendzovsky, one of 10 2009 American Brain Tumor Medical ... Scientific Advisory Council. Ksendzovsky,s research focused on a vaccine ...
Cached Medicine News:Health News:Stain repellent chemical linked to thyroid disease in adults 2Health News:Stain repellent chemical linked to thyroid disease in adults 3Health News:Bravo's 'Real Housewife' Comes to Boca Raton, Florida 2Health News:Park Avenue Podiatric Care Opens New Office in Staten Island Specializing in Cosmetic Foot Surgery 2Health News:Park Avenue Podiatric Care Opens New Office in Staten Island Specializing in Cosmetic Foot Surgery 3Health News:Older brains make good use of 'useless' information 2
... Concentrator offers all the great features of Platinum ... lifecycle costs. Platinum XL features an upgraded compressor, ... required by 40%! Platinum XL also offers an ... years with no hour limit on the compressor! ...
... Platinum 10 concentrator. The Platinum 10 delivers ... have come to expect from the Platinum ... alternative to liquid systems. The Platinum 10 ... for high flow patients, and has less ...
... Expected availability is November 2005. Specifications, ... ,At less than 5 lb (2.3 kg), ... oxygen concentrator tailored specifically for those patients ... like its name suggests, FreeStyle captures the ...
... Has improved the quality of life for ... providers a quality product designed with state-of-the-art ... less than 50 pounds can operate through ... of coverage warranties. The M600/605 series with ...
Medicine Products: